Role of the hydrogen bonding heteroatom-lys53 interaction between the p38r mitogen-activated protein (map) kinase and pyridinyl-substituted 5-membered heterocyclic ring inhibitors

Journal of Medicinal Chemistry

Volumn 52, Issue 8, 2009, Pages 2613-2617

  Thaher, Bassam Abu ^a   Koch, Pierre ^b   Schattel, Verena ^b   Laufer, Stefan ^b  

^a ISLAMIC UNIVERSITY OF GAZA   (Palestine)

^b UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

2 (4 FLUOROPHENYL) 3 (PYRIDIN 4 YL) 1H PYRROLE; 2 (4 FLUOROPHENYL) 3 (PYRIDIN 4 YL)FURAN; 4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; 4 (4 FLUOROPHENYL) 5 (PYRIDIN 4 YL) 1H IMIDAZOLE; CYCLOPENTENE DERIVATIVE; FURAN DERIVATIVE; HETEROCYCLIC COMPOUND; IMIDAZOLE DERIVATIVE; LYSINE; MITOGEN ACTIVATED PROTEIN KINASE 14; PYRIDINE DERIVATIVE; PYRROLE DERIVATIVE; UNCLASSIFIED DRUG;

ARTICLE; DRUG SYNTHESIS; ENZYME INHIBITION; HYDROGEN BOND; IC 50; MOLECULAR INTERACTION; PHARMACOPHORE;

CYCLOPENTANES; FURANS; HYDROGEN BONDING; IMIDAZOLES; MITOGEN-ACTIVATED PROTEIN KINASE 14; PYRIDINES; PYRROLES; STRUCTURE-ACTIVITY RELATIONSHIP; THERMODYNAMICS;

EID: 65249130003     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm801467h     Document Type: Article

References (27)

1. Kumar, S.; Boehm, J.; Lee, J. C. p38 MAP kinases: key signalling molecules as therapeutic targets for inflammatory diseases. Nat. Rev. Drug Discovery 2003, 2 , 717-726.
2. Lee, J. C.; Kassis, S.; Kumar, S.; Badger, A.; Adams, J. L. p38 mitogen-activated protein kinase inhibitors--mechanisms and therapeutic potentials. Pharmacol. Ther. 1999, 82 , 389-397.
3. Lee, M. R.; Dominguez, C. MAP kinase p38 inhibitors: Clinical results and an intimate look at their interactions with p38a protein. Curr. Med. Chem. 2005, 12 , 2979-2994.
4. Wang, Z.; Canagarajah, B. J.; Boehm, J. C.; Kassisa, S.; Cobb, M. H.; Young, P. R.; Abdel-Meguid, S.; Adams, J. L.; Goldsmith, E. J. Structural basis of inhibitor selectivity in MAP kinases. Structure 1998, 6 , 1117-1128.
5. Toledo, L. M.; Lydon, N. B.; Elbaum, D. The structure-based design of ATP-site directed protein kinase inhibitors. Curr. Med. Chem. 1999, 6 , 775-805.
6. Wrobleski, S. T.; Doweyko, A. M. Structural comparison of p38 inhibitor-protein complexes: A review of recent p38 inhibitors having unique binding interactions. Curr. Top. Med. Chem. (Sharjah, United Arab Emirates) 2005, 5 , 1005-1016.
7. Laufer, S. A.; Wagner, G. K. From Imidazoles to Pyrimidines: New Inhibitors of Cytokine Release. J. Med. Chem. 2002, 45 , 2733-2740.
8. Gallagher, T. F.; Seibel, G. L.; Kassis, S.; Laydon, J. T.; Blumenthal, M. J.; Lee, J. C.; Lee, D.; Boehm, J. C.; Fier-Thompson, S. M. Regulation of stress-induced cytokine production by pyridinylimidazoles; inhibition of CSBP kinase. Bioorg. Med. Chem. 1997, 5 , 49- 64.
9. Fitzgerald, C. E.; Patel, S. B.; Becker, J. W.; Cameron, P. M.; Zaller, D.; Pikounis, V. B.; O'Keefe, S. J.; Scapin, G. Structural basis for p38a MAP kinase quinazolinone and pyridol-pyrimidine inhibitor specificity. Nat. Struct. Biol. 2003, 10 , 764-769.
10. de Laszlo, S. E.; Hacker, C; Li, B.; Kim, D.; MacCoss, M.; Mantlo, N.; Pivnichny, J. V.; Colwell, L.; Koch, G. E.; Cascieri, M. A.; Hagmann, W. K. Potent, orally absorbed glucagon receptor antagonists. Bioorg. Med. Chem. Lett. 1999, 9 , 641-646.
11. de Laszlo, S. E.; Visco, D.; Agarwal, L.; Chang, L.; Chin, J.; Croft, G.; Forsyth, A.; Fletcher, D.; Frantz, B.; Hacker, C.; Hanlon, W.; Harper, C.; Kostura, M.; Li, B.; Luell, S.; MacCoss, M.; Mantlo, N.; O'Neill, E. A.; Orevillo, C; Pang, M.; Parsons, J.; Rolando, A.; Sahly, Y.; Sidler, K.; Widmer, W. R.; O'Keefe, S. J. Pyrroles and other heterocycles as inhibitors of p38 kinase. Bioorg. Med. Chem. Lett. 1998, 8 , 2689-2694.
12. Steiner, T. Reviews: The hydrogen bond in the solid state. Angew. Chem., Int. Ed. 2002, 41 , 48-76.
13. Hao, M. H. Theoretical Calculation of Hydrogen-Bonding Strength for Drug Molecules. J Chem. Theory Comput 2006, 2 , 863-872.
14. Umeyama, H.; Morokuma, K. The origin of hydrogen bonding. An energy decomposition study. J. Am. Chem. Soc. 1977, 99 , 1316- 1332.
15. Abu Thaher, B.; Koch, P.; Del Amo, V.; Knochel, P.; Laufer, S. A convenient synthesis of 1-
16. (4-fluorophenyl) -2-
17. (4-pyridyl) cyclopentene from cyclopentanone. Synthesis 2008, 225 -228.
18. Qian, X.; Liang, G. B.; Feng, D.; Fisher, M.; Crumley, T.; Rattray, S.; Dulski, P. M.; Gurnett, A.; Leavitt, P. S.; Liberator, P. A.; Msura, A. S.; Samaras, S.; Tamas, T.; Schmatz, D. M.; Wyvratt, M.; Biftu, T. Synthesis and SAR studies of diarylpyrrole anticoccidial agents. Bioorg. Med. Chem. Lett. 2006, 16 , 2817-2821.
19. Boehm, J. C; Smietana, J. M.; Sorenson, M. E.; Garigipati, R. S.; Gallagher, T. F.; Sheldrake, P. L.; Bradbeer, J.; Badger, A. M.; Laydon, J. T.; Lee, J. C.; Hillegass, L. M.; Griswold, D. E.; Breton, J. J.; Chabot-Fletcher, M. C.; Adams, J. L. 1-substituted 4-aryl-5-pyridinylimidazoles: a new class of cytokine suppressive drugs with low 5-lipoxygenase and cyclooxygenase inhibitory potency. J. Med. Clien. 1996, 39 , 3929-3937.
20. Wolkenberg, S. E.; Wisnoski, D. D.; Leister, W. H.; Wang, Y.; Zhao, Z.; Lindsley, C. W. Efficient synthesis of imidazoles from aldehydes and 1, 2-diketones using microwave irradiation. Org. Lett. 2004, 6 , 1453-1456.
21. Laufer, S.; Thuma, S.; Peifer, C.; Greim, C.; Herweh, Y.; Albrecht, A.; Dehner, F. An immunosorbent, nonradioactive p38 MAP kinase assay comparable to standard radioactive liquid-phase assays. Anal. Biochem. 2005, 344 , 135-137.
22. Abu Thaher, B.; Koch, P.; Schollmeyer, D.; Laufer, S. 4- (2- (4- Fluorophenyl) -1H-pyrrol-3-yl) pyridine. Acta Crystallogr., Sect. E: Struct. Rep. Online 2009, E65 , o457.
23. Abu Thaher, B.; Koch, P.; Schollmeyer, D.; Laufer, S. 4- (2- (4- Fluorophenyl) furan-3-yl) pyridine. Acta Crystallogr., Sect. E: Struct. Rep. Online 2009, E65 , o458.
24. Koch, P.; Schollmeyer, D.; Laufer, S. 4- (5- (4-Fluorophenyl) -1 H imidazol-4-yl) pyridine. Acta Crystallogr., Sect. E: Struct. Rep. 2009, E65 , o573.
25. Jaguar v 7.0; Schroedinger Inc., LLC: New York, NY, 2007.
26. Jaguar v 7.5; Schroedinger Inc., LLC: New York, NY, 2008.
27. Schroedinger Suite 2008, Induced Fit Docking Protocol; Glide version 5.0; Schroedinger, LLC: New York, 2005. DOI: 10.1021/jm801594x